	US 12,295,960 B2
	Cancer treatment
Robert W. Sobol, Providence, RI (US); and Jay George, Gaithersburg, MD (US)
Assigned to UNIVERSITY OF SOUTH ALABAMA FOUNDATION FOR RESEARCH AND COMMERCIALIZATION, Mobile, AL (US); and CANAL HOUSE BIOSCIENCES, LLC, Providence, RI (US)
Appl. No. 18/571,452
Filed by University of South Alabama Foundation for Research and Commercialization, Mobile, AL (US); and Canal House Biosciences, LLC, Providence, RI (US)
PCT Filed Oct. 17, 2022, PCT No. PCT/US2022/046832 § 371(c)(1), (2) Date Dec. 18, 2023, PCT Pub. No. WO2023/064619, PCT Pub. Date Apr. 20, 2023.
Claims priority of provisional application 63/256,595, filed on Oct. 17, 2021.
Prior Publication US 2024/0285647 A1, Aug. 29, 2024
Int. Cl. A61K 31/5517 (2006.01); A61K 31/145 (2006.01); A61K 31/4045 (2006.01); A61K 31/454 (2006.01); A61K 31/501 (2006.01); A61K 31/502 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); G01N 33/68 (2006.01)

CPC A61K 31/5517 (2013.01) [A61K 31/145 (2013.01); A61K 31/4045 (2013.01); A61K 31/454 (2013.01); A61K 31/501 (2013.01); A61K 31/502 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); G01N 33/6893 (2013.01); G01N 2333/4703 (2013.01)]

5 Claims

1. A method for the treatment of a cancer, which comprises administering to a subject in need of such treatment:

a) a pharmaceutically effective amount of a compound that increases the amount of NAD⁺ in the subject's cancer cells, and

b) a pharmaceutically effective amount of a PARG inhibitor and optionally one or more PARP inhibitors, wherein the compound that increases the amount of NAD⁺ comprises dihydronicotinamide riboside (NRH), the PARG inhibitor comprises (E)-1-(((p-Tolylthio)imino)methyl) naphthalen-2-ol, and the cancer is a glioma.